Login to Your Account

Deals And M&A NEWS

Astrazeneca plc is in both giving and receiving mode as it moves to expand its immuno-oncology portfolio, simultaneously announcing a $1.275 billion in-licensing agreement with French biotech Innate Pharma SA and the out-licensing of rights to develop its MEDI4736 anti-PD-L1 antibody in hematological cancers to Celgene Corp.

Having banked $38 million in a series A round late last year, cancer immunotherapy firm Potenza Therapeutics Inc. is "in good shape in terms of financing," thanks also to an undisclosed amount of new money from a deal with Astellas Pharma Inc., CEO Daniel Hicklin noted.

Teva Pharmaceutical Industries Ltd., the world's largest generic drugmaker, put an end to speculation about its interest in acquiring Mylan NV on Tuesday, making a $40.1 billion bid for the generics heavyweight, valuing it at $82 per share in a half cash, half stock offer.
More Deals And M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: